Innovating.works Conecta tu I+D

Showing 1 to 20 of 35 results

Secreters: A new generation of microbial expression hosts and tools for the production of biotherapeutics and h... UCB PHARMA SA participó en un H2020: H2020-MSCA-ITN-2018 The ‘SECRETERS’ partnership aims to bring about a step change in the production of recombinant proteins, particularly Biotherapeutics and In...
2018-08-30 - 2023-06-30 | Financiado

ISOTOPICS: ISOTOPIC LABELING FOR DRUG INNOVATION UCB PHARMA SA participó en un H2020: H2020-MSCA-ITN-2015 Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Meta...
2015-08-10 - 2019-12-31 | Financiado

EVOluTION: European Vascular Interventions and Therapeutic Innovation Network UCB PHARMA SA participó en un H2020: H2020-MSCA-ITN-2015 EVOluTION, a pioneering network within EU in view of its focus on endogenous protective mechanisms, is formed to provide training for 11 you...
2015-08-07 - 2020-03-31 | Financiado

ProteinFactory: Engineering of new generation protein secretion systems UCB PHARMA SA participó en un H2020: H2020-MSCA-ITN-2014 The market for recombinant proteins, including biopharmaceuticals, industrial enzymes and membrane proteins, is estimated to be about 78 bil...
2014-12-10 - 2018-12-31 | Financiado

eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems UCB PHARMA SA participó en un H2020: H2020-MSCA-ITN-2014 Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado

EBISC: European Bank for induced pluripotent Stem Cells UCB PHARMA SA participó en un FP6: EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, d...
2014-01-01 - 2017-12-31 | Financiado

EUC²LID: European Lead Factory UCB PHARMA SA participó en un FP6: The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as...
2013-01-01 - 2018-05-31 | Financiado

ABIRISK: Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the ri... UCB PHARMA SA participó en un FP6: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
2012-03-01 - 2018-02-28 | Financiado

DDMORE: Drug Disease Model Resources UCB PHARMA SA participó en un FP6: Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD...
2011-03-01 - 2016-08-31 | Financiado

ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... UCB PHARMA SA participó en un FP6: The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
2010-01-01 - 2016-12-31 | Financiado

MARCAR: bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis UCB PHARMA SA participó en un FP6: MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism...
2010-01-01 - 2015-06-30 | Financiado

PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... UCB PHARMA SA participó en un FP6: PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado

U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes UCB PHARMA SA participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado

EUROPAIN: Understanding chronic pain and improving its treatment UCB PHARMA SA participó en un FP6: We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
2009-10-01 - 2015-09-30 | Financiado

EU2P: European programme in Pharmacovigilance and Pharmacoepidemiology UCB PHARMA SA participó en un FP6: The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia...
2009-09-01 - 2016-06-30 | Financiado

PRO- ACTIVE: Physical Activity as a Crucial Patient Reported Outcome in COPD UCB PHARMA SA participó en un FP6: Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have l...
2009-09-01 - 2016-05-31 | Financiado

CCT-MicroIndus: Continuous Catalytic Transformations from optimization in MICRO systems to INDustrial production UCB PHARMA SA tramitó un FP7: This project is aiming at providing the training for 2 ESR in the framework of a integrated approach for heterogeneous catalysis in continuo...
Financiado

EUROPAIN: Understanding chronic pain and improving its treatment UCB PHARMA SA participó en un FP7: We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
Financiado

ABIRISK: Anti Biopharmaceutical Immunization Prediction and analysis of clinical relevance to minimize the ri... UCB PHARMA SA participó en un FP7: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
Financiado

ETOX: Integrating bioinformatics and chemoinformatics approaches for the development of expert systems all... UCB PHARMA SA participó en un FP7: The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological pr...
Financiado